Although some uncommon EGFR mutations were reported to derive clinical benefit from immunotherapy,21, 22 the correlation between NSCLC with EGFR ex20ins and its response to ICI was controversial by several studies, covering a possible trend that ICI might not be a favorable option for ex20ins patients.8, 10, 12, 22, 23, 24, 25, 26. Here, EGFR is linked to non-small cell lung carcinoma.